Results 81 to 90 of about 85,599,608 (253)

Trends in the utilization, expenditure and costs of noninsulin glucose‐lowering drugs in the Medicaid population: Steady increases in glucagon‐like peptide‐1 receptor agonist and sodium–glucose transporter‐2 inhibitor use, prices and expenditure

British Journal of Clinical Pharmacology, EarlyView.
Aims This study aimed to analyse changes in the utilization, expenditure and average cost of noninsulin glucose‐lowering drugs (GLDs) between 2008 and 2023. Methods This was a retrospective observational study of 2008–2023 data from the National Medicaid State Drug Utilization database.
Rawan O. Almadfaa
wiley   +1 more source

Weight neutrality with the DPP-4 inhibitor, vildagliptin: Mechanistic basis and clinical experience

, 2010
James E Foley1, Jens Jordan21Clinical Research and Development, Novartis Pharmaceutical Corporation, East Hanover, New Jersey, USA; 2Institute for Clinical Pharmacology, Hannover Medical School, Hannover, GermanyAbstract: Various factors may confound how
James E Foley, Jens Jordan
core  

DPP-4 activity affected by the presence of Myr and HP (μmol/mg/min).

, 2020
DPP-4 activity affected by the presence of Myr and HP (μmol/mg/min).
Talahalli Ravichandra Ramaprasad (8703693), Bettadahalli Sadashivaiah (8703690), Nanjaiah Lalitha (8703687), Sridevi Annapurna Singh (8703696)   +3 more
core   +1 more source

Blood pressure effects of SGLT2 inhibitors and GLP‐1 receptor agonists: Mechanisms, trial evidence and Real‐world data

British Journal of Clinical Pharmacology, EarlyView.
SGLT2 inhibitors and GLP‐1 receptor agonists modestly lower blood pressure across diverse patient populations, including those without diabetes. These effects appear largely independent of glycaemic control and offer additive value in high‐risk patients with overlapping comorbidities.
Andrej Belančić, Yusuf Ziya Sener, Marijana Vučković, Joseph Edgar Blais, Almir Fajkić, Emina Sher, Mislav Radić, Josipa Radić   +7 more
wiley   +1 more source

STUDI IN SILICO POTENSI SENYAWA ALLIIN BAWANG PUTIH (Allium sativum) SEBAGAI INHIBITOR DPP-4 PADA DIABETES MELLITUS

Jurnal Ilmiah Medicamento, 2018
Diabetes mellitus (DM) merupakan penyakit gangguan metabolisme glukosa yang dicirikan dengan gangguan sekresi dan resistensi insulin. Jalur pengobatan DM baru pada sistem increatin dengan penghambatan terhadap DPP-4 telah dikembangkan dan terbukti ...
Martina Kurnia Rohmah
doaj   +5 more sources

Concomitant Use of DPP‐4 Inhibitors May Prevent the Development of Oxaliplatin‐Induced Peripheral Neuropathy: A Retrospective Cohort Study

Clinical and Translational Science
Oxaliplatin‐induced peripheral neuropathy (OIPN) causes numbness and pain in the limbs, often leading to interruption of chemotherapy and representing a significant clinical problem.
Yusuke Koura, Keisuke Mine, Shunsuke Fujita, Takehiro Kawashiri, Yusuke Mori, Mami Ueda, Risa Kaneko, Takeshi Hirota, Mayako Uchida, Daisuke Kobayashi   +9 more
doaj   +1 more source

Population Pharmacokinetic/Pharmacodynamic Analysis of the DPP-4 Inhibitor Linagliptin in Japanese Patients with Type 2 Diabetes Mellitus

Journal of Pharmacy & Pharmaceutical Sciences, 2013
[Objectives] Linagliptin is a novel, highly selective and long acting DPP-4 inhibitor for the treatment of type 2 diabetes mellitus (T2DM). Linagliptin exhibits non-linear pharmacokinetics (PK) due to saturable binding to plasma and tissue DPP-4. The aim
Yusuke Tadayasu, Akiko Sarashina, Yasuhiro Tsuda, Shinji Tatami, Christian Friedrich, Silke Retlich, Alexander Staab, Mikihisa Takano   +7 more
doaj   +1 more source

Exposure‐adjusted safety and efficacy of GLP‐I and GLP‐1/GIP receptor agonists compared with non‐GLP‐I for weight management and type 2 diabetes: Based on FDA medical and statistical reports of 34 280 safety and 36 312 efficacy subjects

British Journal of Clinical Pharmacology, EarlyView.
Aims This work aimed to contextualize glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) and glucose‐dependent insulinotropic polypeptide (GIP) receptor agonists safety and efficacy regarding weight management (WM); we analysed Food and Drug Administration (FDA) Medical Reviews to analyse 14 medications using patient‐exposure year normalization and ...
Aishwarya Prasad, Anshu Arora, Arun Arora, Jeena Vaid, Arif Khan   +4 more
wiley   +1 more source

Association of DPP-4 inhibitors with respiratory and cardiovascular complications in patients with COPD: a nationwide cohort study

ERJ Open Research
Aims COPD is a comorbid condition often associated with type 2 diabetes (T2D) and cardiovascular diseases, but few studies have observed the impact of various antidiabetic drugs in patients with COPD and T2D.
Fu-Shun Yen, James Cheng-Chung Wei, Fu-Shun Ko, Yuhan Huang, Hei-Tung Yip, Fuu-Jen Tsai, Chii-Min Hwu, Chih-Cheng Hsu   +7 more
doaj   +1 more source

The perceptions of natural compounds against dipeptidyl peptidase 4 in diabetes: from to

Therapeutic Advances in Chronic Disease, 2019
Dipeptidyl peptidase IV (DPP-4), an incretin glucagon-like peptide-1 (GLP-1) degrading enzyme, contains two forms and it can exert various physiological functions particular in controlling blood glucose through the action of GLP-1.
Shian-Ren Lin, Chia-Hsiang Chang, May-Jwan Tsai, Henrich Cheng, Jian-Chyi Chen, Max K. Leong, Ching-Feng Weng   +6 more
doaj   +1 more source